Clinical Trials Insight: 700028031
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 03 Nov 2007
At a glance
- Drugs HE 3286 (Primary)
- Indications Insulin resistance; Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Harbor Therapeutics
- 03 Nov 2007 This trial is expected to be initiated in quarter 2 of 2008.
- 01 Nov 2007 New trial record.